Menu
Global leading candidate in Phase 2b for the treatment of adenoviral conjunctivitis.
With acute conjunctivitis representing 1% of all primary care visits in the US, we see a significant need and opportunity.
© 2021 Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS